Format

Send to

Choose Destination
Thromb Res. 2014 Mar;133(3):315-21. doi: 10.1016/j.thromres.2013.12.004. Epub 2013 Dec 6.

Carbon monoxide: Anticoagulant or procoagulant?

Author information

1
The Department of Anesthesiology, The University of Arizona College of Medicine, Tucson, AZ, USA. Electronic address: vgnielsen@email.arizona.edu.
2
The Department of Physiology, Faculty of Health Sciences, University of Pretoria, Arcadia, South Africa.

Abstract

Within the past decade there have been several investigations attempting to define the impact of exogenous and endogenous carbon monoxide exposure on hemostasis. Critically, two bodies of literature have emerged, with carbon monoxide mediated platelet inhibition cited as a cause of in vitro human and in vitro/in vivo rodent anticoagulation. In contrast, interaction with heme groups associated with fibrinogen, α₂-antiplasmin and plasmin by carbon monoxide has resulted in enhanced coagulation and decreased fibrinolysis in vitro in human and other species, and in vivo in rabbits. Of interest, the ultrastructure of platelet rich plasma thrombi demonstrates an abnormal increase in fine fiber formation and matting that are obtained from humans exposed to carbon monoxide. Further, thrombi obtained from humans and rabbits have very similar ultrastructures, whereas mice and rats have more fine fibers and matting present. In sum, there may be species specific differences with regard to hemostatic response to carbon monoxide. Carbon monoxide may be a Janus-faced molecule, with potential to attenuate or exacerbate thrombophilic disease.

KEYWORDS:

Carbon monoxide; Coagulation; Fibrinogen; Fibrinolysis; Platelet

PMID:
24360115
DOI:
10.1016/j.thromres.2013.12.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center